Tasisulam

DB11941InvestigationalSmall molecule

Tasisulam has been used in trials studying the treatment and basic science of Melanoma, Lymphoma, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.

Mechanism: Pharmacologically active on RNA-binding protein 39
Curator reviewed
Formula / weight: C₁₁H₆BrCl₂NO₃S₂ · 415.1 g/mol (avg)
Code names: LY-573636

Resolves to

Compound

UNII1YC4W9MSLJCAS519055-62-0ChEMBLCHEMBL2110587PubChem10160238

Structure

InChIKeyWWONFUQGBVOKOF-UHFFFAOYSA-NSMILESClC1=CC(Cl)=C(C=C1)C(=O)NS(=O)(=O)C1=CC=C(Br)S1

Targets

Q14498RBM39

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tasisulam, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account